Gilead Sciences, Inc. $GILD Stock Position Raised by Howard Capital Management Inc.

Howard Capital Management Inc. increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,094 shares of the biopharmaceutical company’s stock after acquiring an additional 5,702 shares during the quarter. Howard Capital Management Inc.’s holdings in Gilead Sciences were worth $4,334,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences during the 1st quarter worth $25,000. GoalVest Advisory LLC boosted its holdings in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Activest Wealth Management boosted its holdings in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences during the second quarter worth about $27,000. Finally, Colonial Trust Advisors increased its holdings in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 213 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

NASDAQ GILD opened at $120.47 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $124.61. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market capitalization of $149.48 billion, a PE ratio of 24.00, a P/E/G ratio of 0.83 and a beta of 0.34. The company’s 50 day simple moving average is $115.52 and its 200 day simple moving average is $111.21.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares in the company, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the transaction, the insider owned 110,193 shares of the company’s stock, valued at approximately $13,011,589.44. This trade represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,500 shares of company stock worth $7,142,140 over the last 90 days. 0.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

GILD has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Wolfe Research raised their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, October 23rd. Cantor Fitzgerald lifted their price target on Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a report on Friday, July 25th. Finally, Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the company from $108.00 to $127.00 in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.61.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.